KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Current Liabilities (2016 - 2025)

Ionis Pharmaceuticals has reported Total Current Liabilities over the past 17 years, most recently at $781.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $781.6 million for Q4 2025, up 152.67% from a year ago — trailing twelve months through Dec 2025 was $781.6 million (up 152.67% YoY), and the annual figure for FY2025 was $781.6 million, up 152.67%.
  • Total Current Liabilities for Q4 2025 was $781.6 million at Ionis Pharmaceuticals, down from $903.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for IONS hit a ceiling of $903.5 million in Q3 2025 and a floor of $228.4 million in Q1 2022.
  • Median Total Current Liabilities over the past 5 years was $299.8 million (2021), compared with a mean of $384.0 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 59.83% in 2021 and later soared 196.64% in 2025.
  • Ionis Pharmaceuticals' Total Current Liabilities stood at $240.6 million in 2021, then rose by 29.52% to $311.6 million in 2022, then skyrocketed by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024, then soared by 152.67% to $781.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $781.6 million (Q4 2025), $903.5 million (Q3 2025), and $897.2 million (Q2 2025) per Business Quant data.